Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 1/20 | 0.30 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.30 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9967701 | 0.81 | ALDH1A1 (0.36) | CACNA1GCACNA1HCACNA1I | |
| SCHEMBL13792445 | 0.81 | CACNA1G (0.31) | CACNA1GCACNA1HCACNA1I | |
| SCHEMBL2186518 | 0.79 | CACNA1G (0.33) | CACNA1GCACNA1HCACNA1I | |
| SCHEMBL16077753 | 0.79 | CACNA1G (0.33) | CACNA1GCACNA1HCACNA1I | |
| SCHEMBL19608885 | 0.79 | CACNA1G (0.30) | CACNA1GCACNA1HCACNA1I | |
| Hydrochloric Acid SCHEMBL27759033 | 0.78 | CACNA1G (0.34) | CACNA1GCACNA1HCACNA1I | |
| SCHEMBL24538159 | 0.76 | — | — | |
| SCHEMBL15341602 | 0.76 | KMT2A (0.34) | CACNA1GCACNA1HCACNA1I | |
| SCHEMBL22843159 | 0.76 | MAPT (0.33) | CACNA1GCACNA1HCACNA1I | |
| SCHEMBL22927485 | 0.76 | ADORA2A (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3774775-B1 | 4-OXO-3,4-DIHYDROQUINAZOLINE COMPOUNDS AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2023-10-11 | — | — | EP | disclosed |
| US-10316031-B2 | Compositions and methods for inhibiting kinases | INHIBIKASE THERAPEUTICS, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20180057488-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | INHIBIKASE THERAPEUTICS, INC. | 2018-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10316031-B2 | Compositions and methods for inhibiting kinases | MAP3K1, PACSIN2, MAP3K3 | CACNA1G 4669/4885CACNA1H 4673/4885CACNA1I 4716/4885 |
| US-20180057488-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | MAP3K1, PACSIN2, MAP3K3 | CACNA1G 4669/4885CACNA1H 4673/4885CACNA1I 4716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.